Recent News

• 02.13.2026 - Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
• 02.12.2026 - Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
• 01.06.2026 - Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 01.05.2026 - Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
• 12.08.2025 - Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Recent Filings

• 02.13.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.12.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.05.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.04.2026 - 8-K Current report
• 01.30.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.23.2026 - 8-K Current report
• 01.23.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.22.2026 - 4 Statement of changes in beneficial ownership of securities